At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 228 enrolled
Drug / intervention
NYX-2925 50 mg +1 moredrug
Likely dose
NYX-2925 50 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of NYX-2925 in Subjects With Neuropathic Pain Associated With Diabetic Peripheral Neuropathy
In Brief
A Phase 2 clinical trial evaluating NYX-2925 50 mg and Placebo for Diabetic Peripheral Neuropathic Pain. Completed, enrolled 228 participants across 35 sites.
Detailed Summary
To evaluate the efficacy of NYX-2925 versus placebo in treating the neuropathic pain associated with diabetic peripheral neuropathy.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetic Peripheral Neuropathic Pain
CountriesUnited States
CollaboratorsWorldwide Clinical Trials
Timeline
Phase 2CompletedFinished
2020202120222023202420252026
First PostedOct 2019
Enrollment StartNov 2019
Primary CompletionFeb 2022
TodayJul 2026
First PostedOct 31, 2019
Enrollment StartNov 12, 2019
Primary CompletionFeb 23, 2022
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 6.7 years ago
Interventions
NYX-2925 50 mgdrug
NYX-2925 administered orally
Placebodrug
Placebo administered orally